Okogen, Inc.
Other · Plano, Texas
Okogen, Inc. is a other company based in Plano, Texas, incorporated in 2016. It has reported $8.9 million raised across 3 Form D filings with the SEC, most recently in 2024.
Innovating the Pink Eye Treatment Landscape Leading candidate in Phase 2B for the treatment of Acute Infectious Conjunctivitis. Research & Development Enhancing Lives Through Better Vision Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis, including […]
| Date | Round | Amount | Raised to date | Lead investor | Source |
|---|---|---|---|---|---|
| 2024-12-12 | — | $2.5M | $8.9M | SEC Form D | |
| 2024-01-09 | — | $213K | $6.4M | SEC Form D | |
| 2017-12-29 | — | $6.2M | $6.2M | SEC Form D |
SEC rows are Form D filings, where the amount is what was actually sold and amendments update a round rather than adding one. Press rows are split between company-issued releases or wires and editorial or third-party coverage. The total is therefore a floor: a round nobody reported is a round we cannot see. A buyout or control change appears in the timeline but is never added to the total: that money goes to shareholders, not into the company.
Form D is the notice a company files with the SEC when it sells securities without registering them. It reports the amount sold, not a valuation. Figures here are what the filing says. Where a filing is silent, the field is left blank rather than estimated. “Total raised” adds press-reported rounds that never appear in a filing, so it is a floor rather than an audited sum: press amounts are the figures the company announced, and a round nobody reported is a round we cannot see.